|
5.5.1 ASCO (général)
|
|
|
|
|
ASCO 2015: Abstract Thoughts On Cancer And Competition [Forbes]
|
|
|
|
|
|
The
industry is largely chasing all the same cancer targets; once validated
with clinical data, competition on these emerging high impact targets
becomes fierce – as is the case with many of the ErbB and
immuno-oncology checkpoint targets today, as well as CD-19 in the CAR-T
space.
|
|
|
|
|
|
|
|
5.5.1.1 ASCO (général) - Industriels
|
|
|
|
|
|
|
5.5.10 ASCO (hémato)
|
|
|
|
|
|
|
|
|
|
5.5.11 ASCO (SNC]
|
|
|
|
|
|
5.5.12 ASCO (médico-éco)
|
|
|
Bristol-Myers Squibb Has A Cancer Breakthrough. Here's Why It Should Cut The Price [Forbes]
|
|
|
|
|
|
For
Merck and Roche, this is an opportunity: if doctors and insurers that
patients with high levels of PD-L1 don’t need the combo, they can
compete in that part of the melanoma market. But there’s an obvious way
for Bristol to prevent this: the company could give a discount on Opdivo
and Yervoy when the drugs are purchased together, thereby reducing the
combo’s sky-high cost and helping to lock up the market. Will it?
|
|
|
|
|
|
|
High Drug Prices Attacked at Meeting [Wall Street Journal]
|
|
|
|
|
|
Dr.
Saltz said the combination regimen’s benefit was “truly, truly
remarkable for a disease that five years ago we thought was virtually
untreatable.” But he said that combining the drugs would cost around
$295,000 a patient over nearly one year, which he called unsustainable.
|
|
|
|
|
|
|
5.5.13 ASCO (divers)
|
|
|
Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting [Myriad]
|
|
|
|
|
|
The
myRisk Hereditary Cancer test assesses 25 genes for mutations
associated with eight hereditary cancers. Finding deleterious mutations
in these genes can help patients with cancer receive appropriate medical
care and reduce the risk of second cancers, while patients without
cancer can take steps in consultation with their healthcare provider to
lower their risk of developing cancer.
|
|
|
|
|
|
|
|
|
Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting [Myriad]
|
|
|
|
|
|
The
myRisk Hereditary Cancer test assesses 25 genes for mutations
associated with eight hereditary cancers. Finding deleterious mutations
in these genes can help patients with cancer receive appropriate medical
care and reduce the risk of second cancers, while patients without
cancer can take steps in consultation with their healthcare provider to
lower their risk of developing cancer.
|
|
|
|
|
|
|
|
5.5.2 ASCO (sein)
|
|
|
|
|
Pfizer's Ibrance drug slows progression of breast cancer [Reuters]
|
|
|
|
|
|
At
the time of an interim analysis, patients given Ibrance
(palbociclib)and AstraZeneca Plc's Faslodex (fulvestrant), a widely used
treatment to block estrogen, lived an average of 9.2 months before
their cancer worsened. This compared with 3.8 months for patients
treated with Faslodex and a placebo.
|
|
|
|
|
|
|
Some older breast cancer patients may skip invasive biopsy [Reuters]
|
|
|
|
|
|
Researchers
followed 140 women aged 70 or older who generally had smaller,
slow-growing tumors. Even though none of the women got a so-called
sentinel node biopsy to see where the tumors might have spread, over the
next five years only four of them died of breast cancer.
|
|
|
|
|
|
|
5.5.4 ASCO (immunothérapies)
|
|
|
|
|
New Immunotherapies for Multiple Hard-to-Treat Cancers [ASCO]
|
|
|
|
|
|
The
new study results demonstrate the effectiveness of immunotherapy drugs
targeting the PD-1 protein in advanced liver, head and neck, lung, and
colorectal cancers. Several of the studies also identified genomic
markers that can be used to determine which patients stand to benefit
most from these new therapies.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.5.5 ASCO (gastro-intestinal)
|
|
|
|
5.5.6 ASCO (peau)
|
|
|
|
|
|
|
|
|
|
|
5.5.8 ASCO (poumon)
|
|
|
|
|
|
|
Lung cancer therapy is 'milestone' [BBC News]
|
|
|
|
|
|
There
are still big questions to be answered. The long-term consequences of
modifying the immune system are still unknown and the best way of
figuring out who will respond to therapy is uncertain. And these
therapies are also likely to be very expensive and so will pose a
challenge for health services trying to offer them
|
|
|
|
|
|
|
|
Bristol's Opdivo cuts risk of lung cancer death for some [Reuters]
|
|
|
|
|
|
The
Phase III trial found that Opdivo, part of a new class of drugs that
harness the immune system to fight cancer, reduced by 27 percent the
risk of death from advanced non-squamous non-small cell lung cancer
(NSCLC), compared with chemotherapy. The benefit reached 60 percent for
patients with the highest levels of the PD-L1 protein.
|
|
|
|
|
|
|
5.5.9 ASCO (autres organes)
|
|
|
|
|